Healthcare provider profile · identity verified

Natalia Nacu, MD

Internal Medicine · YORK, PA · NPI 1801059241

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	314	98
Levothyroxine Sodium	Levothyroxine Sodium	158	45
Lisinopril	Lisinopril	153	48
Gabapentin	Gabapentin	143	40
Losartan Potassium	Losartan Potassium	141	45
Omeprazole	Omeprazole	137	48
Rosuvastatin Calcium	Rosuvastatin Calcium	128	40
Amlodipine Besylate	Amlodipine Besylate	111	37
Alendronate Sodium	Alendronate Sodium	106	21
Pantoprazole Sodium	Pantoprazole Sodium	98	24
Trazodone Hcl	Trazodone Hcl	94	26
Metoprolol Succinate	Metoprolol Succinate	87	25
Metformin Hcl	Metformin Hcl	86	27
Sertraline Hcl	Sertraline Hcl	79	31
Furosemide	Furosemide	77	29
Eliquis	Apixaban	66	16
Carvedilol	Carvedilol	56	15
Escitalopram Oxalate	Escitalopram Oxalate	55	14
Albuterol Sulfate Hfa	Albuterol Sulfate	54	23
Metoprolol Tartrate	Metoprolol Tartrate	51	14
Tamsulosin Hcl	Tamsulosin Hcl	49	17
Hydrochlorothiazide	Hydrochlorothiazide	44	15
Hydralazine Hcl	Hydralazine Hcl	43	14
Duloxetine Hcl	Duloxetine Hcl	36	12
Famotidine	Famotidine	36	14
Spironolactone	Spironolactone	36	suppressed
Jardiance	Empagliflozin	35	suppressed
Meloxicam	Meloxicam	35	11
Pravastatin Sodium	Pravastatin Sodium	35	suppressed
Montelukast Sodium	Montelukast Sodium	34	12
Potassium Chloride	Potassium Chloride	34	11
Alprazolam	Alprazolam	33	suppressed
Lovastatin	Lovastatin	32	suppressed
Nifedipine Er	Nifedipine	32	12
Atenolol	Atenolol	31	suppressed
Glipizide	Glipizide	31	suppressed
Allopurinol	Allopurinol	29	suppressed
Glipizide Er	Glipizide	29	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	28	21
Ozempic	Semaglutide	27	suppressed
Pregabalin	Pregabalin	27	suppressed
Chlorthalidone	Chlorthalidone	25	suppressed
Tramadol Hcl	Tramadol Hcl	25	suppressed
Breo Ellipta	Fluticasone/Vilanterol	24	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	24	suppressed
Simvastatin	Simvastatin	24	12
Quetiapine Fumarate	Quetiapine Fumarate	23	suppressed
Glimepiride	Glimepiride	22	suppressed
Lorazepam	Lorazepam	22	suppressed
Trulicity	Dulaglutide	21	suppressed
Clopidogrel	Clopidogrel Bisulfate	20	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	20	suppressed
Metformin Hcl Er	Metformin Hcl	20	suppressed
Bupropion Xl	Bupropion Hcl	19	suppressed
Fluticasone Propionate	Fluticasone Propionate	18	suppressed
Oxycodone Hcl	Oxycodone Hcl	18	suppressed
Azithromycin	Azithromycin	17	17
Celecoxib	Celecoxib	17	suppressed
Diclofenac Sodium	Diclofenac Sodium	17	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	17	suppressed
Ropinirole Hcl	Ropinirole Hcl	17	suppressed
Brilinta	Ticagrelor	16	suppressed
Cephalexin	Cephalexin	16	13
Fluoxetine Hcl	Fluoxetine Hcl	16	suppressed
Propranolol Hcl	Propranolol Hcl	16	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	16	suppressed
Ipratropium Bromide	Ipratropium Bromide	15	suppressed
Valsartan	Valsartan	15	suppressed
Azelastine Hcl	Azelastine Hcl	14	suppressed
Buspirone Hcl	Buspirone Hcl	14	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	14	suppressed
Fenofibrate	Fenofibrate	14	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	13	suppressed
Meclizine Hcl	Meclizine Hcl	13	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	13	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	12	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Mirtazapine	Mirtazapine	12	suppressed
Estradiol	Estradiol	11	suppressed
Finasteride	Finasteride	11	suppressed
Myrbetriq	Mirabegron	11	suppressed
Prolia	Denosumab	11	suppressed
Rybelsus	Semaglutide	11	suppressed
Synthroid	Levothyroxine Sodium	11	suppressed
Xarelto	Rivaroxaban	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error